Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHARP Oncochip in Metastatic Breast Cancer
2024-513934-40-00Phase 2Authorised
- Sponsor
- European Institute of Oncology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selumetinib, bicalutamide and olaparib in breast cancer (3 arms), sponsored by European Institute of Oncology. Primary endpoint: progression free-survival. Planned start Nov 2024; status: authorised.
02
Drugs
selumetinibbicalutamideolaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-513934-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513934-40-00.